唑来膦酸结合鲑降钙素在原发性骨质疏松患者治疗中的运用效果探究  

Exploration of the Therapeutic Effect of Zoledronic Acid Combined with Salmon Calcitonin in Patients with Primary Osteoporosis

作　　者：薛敏 刘丹 张慧 XUE Min;LIU Dan;ZHANG Hui(Department of Endocrinology,Jingjiang People′s Hospital of Yangzhou University,Jingjiang 214500,Jiangsu,China)

机构地区：[1]扬州大学附属靖江人民医院内分泌科,江苏靖江214500

出　　处：《系统医学》2024年第13期90-93,共4页Systems Medicine

摘　　要：目的研究原发性骨质疏松患者采用唑来膦酸与鲑降钙素联合治疗的效果。方法非随机选择2020年1月—2022年12月扬州大学附属靖江人民医院收治的原发性骨质疏松患者90例。按治疗方法不同将其分成对照组、观察组,各45例,治疗方案分别为单一鲑降钙素、鲑降钙素联合唑来膦酸,治疗周期均为3个月。统计组间治疗有效率、骨代谢与骨密度指标、不良反应发生率。结果观察组总治疗有效率(93.33%)比对照组(77.78%)高,差异有统计学意义(χ^(2)=4.405,P<0.05)。经治疗观察组骨密度指标与25羟维生素D比对照组高,β胶原降解产物比对照组低,差异有统计学意义(P均<0.05);观察组不良反应发生率比对照组高,差异无统计学意义(P>0.05)。结论治疗原发性骨质疏松患者时选择唑来膦酸与鲑降钙素联合用药可提高临床疗效,改善骨代谢与骨密度情况,药物安全性良好。Objective To study the effect of combined treatment with zoledronic acid and salmon calcitonin on pa-tients with primary osteoporosis.Methods A total of 90 patients with primary osteoporosis treated at Jingjiang People's Hospital of Yangzhou University from January 2020 to December 2022 were unrandomly selected as the study subjects.They were divided into the control group and the observation group by difference treatment,with 45 cases each.The treatment plans were single salmon calcitonin and salmon calcitonin combined with zoledronic acid re-spectively,with a treatment period of 3 months for both groups.The effective rate of treatment,bone metabolism and bone density indicators,and incidence of adverse reactions between groups were calculated.Results The total efficacy was higher in observation group(93.33%)than 77.78%in the control group,the difference was statistically significant(χ^(2)=4.405,P<0.05).After treatment,the bone density index and 25(OH)D in the observation group were higher than those in the control group,β-CTX was lower than that in the control group,the differences were statistically signifi-cant(all P<0.05);The number of adverse reactions in the observation group was greater than that in the control group,but the difference was not statistically significant(P>0.05).Conclusion Choosing the combination of zoledronic acid and salmon calcitonin in the treatment of primary osteoporosis patients can improve clinical efficacy,improve bone me-tabolism and bone density,and have good drug safety.

关 键 词：原发性骨质疏松 唑来膦酸 鲑降钙素 骨密度 治疗效果 

分 类 号：R580[医药卫生—内分泌]